Niagen Bioscience CFO presents at Nasdaq X LD Micro SF summit

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • Niagen Bioscience CFO Ozan Pamir presents at Nasdaq X LD Micro SF Summit on September 9, 2026
  • Event features 15-minute presentations and breakout sessions for 25 curated public companies
  • Pamir available for one-on-one meetings with institutional investors in San Francisco
  • Company highlights Tru Niagen as top US NAD+ supplement by revenue in 2025
powered bylight_fuzz_icon
49295202

*this image is generated using AI for illustrative purposes only.

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026, in San Francisco. The event aims to connect curated public companies with institutional investors.

Conference Details

Nasdaq is partnering with LD Micro to host 25 public companies at the Nasdaq San Francisco office. Each company will deliver a 15-minute presentation followed by a dedicated 15-minute breakout session for investor engagement.

Niagen Bioscience CFO Ozan Pamir is scheduled to present at 11:20 am PT. He will also be available for one-on-one meetings with institutional investors during the conference.

Investor Engagement

Investors interested in scheduling a one-on-one meeting with the Niagen Bioscience management team can contact their respective conference representative or email Niagen@KCSA.com .

About Niagen Bioscience

Niagen Bioscience positions itself as the global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. Its product portfolio includes Tru Niagen, described as the number one NAD+ boosting oral supplement in the United States based on revenue per the largest U.S. e-commerce marketplace from January 2025 to December 2025. The company also offers Niagen Plus, featuring pharmaceutical-grade intravenous and injectable products available exclusively at clinics with a prescription.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the outcome of the Nasdaq X LD Micro Summit influence Niagen Bioscience's institutional investor base and stock liquidity in Q4 2026?

What specific growth metrics or clinical data regarding Tru Niagen and Niagen Plus is CFO Ozan Pamir likely to highlight to justify valuation multiples?

Could the exclusive prescription model for Niagen Plus face regulatory or reimbursement hurdles that might impact its projected revenue contribution?

like16
dislike

Niagen Bioscience expands Tru Niagen to 300 GNC, Sam's Club stores

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights

Niagen Bioscience (NASDAQ: NAGE) expanded Tru Niagen availability to nearly 300 GNC and Sam’s Club stores across 44 states. GNC carries the beauty-focused variant and 30-count bottles, while Sam’s Club stocks 120-count bottles. The company cites over 45 human clinical studies and 60 patents supporting its NAD+ technology.

powered bylight_fuzz_icon
48776824

*this image is generated using AI for illustrative purposes only.

Niagen Bioscience (NASDAQ: NAGE) has expanded the retail footprint of its flagship product, Tru Niagen, by securing placement in nearly 300 GNC and Sam’s Club locations across 44 states in the United States. The company stated that this distribution growth places its category-leading NAD+ supplement in front of new consumer audiences, reflecting growing demand for science-backed healthy aging solutions.

Retail Distribution Details

The company differentiated its product offerings between the two retail partners to address specific consumer needs:

  • GNC: Shoppers can purchase Tru Niagen Beauty, described as the first beauty supplement in the US featuring Niagen (patented nicotinamide riboside or NR). This variant supports skin elasticity and the appearance of hair, skin, and nails. GNC also stocks Tru Niagen 300mg 30-count bottles.
  • Sam’s Club: The retailer offers Tru Niagen 300mg 120-count bottles.

Both retailers make these products available in-store and online via www.gnc.com and www.samsclub.com .

Product Science and Market Position

Tru Niagen is powered by Niagen, which the company identifies as the most well-researched and efficient NAD-booster available. The product is clinically shown to increase NAD+ levels, an essential coenzyme for cellular health, mitochondrial function, and DNA repair.

Niagen Bioscience cited the following scientific backing for its portfolio:

  • More than 45 human clinical studies.
  • Over 500 published scientific studies.
  • More than 60 patents worldwide.

The company noted that Tru Niagen is currently the number one healthy-aging NAD-boosting supplement in the United States based on revenue per the largest US e-commerce marketplace from January 2025 to December 2025.

Strategic Outlook

Rob Fried, CEO of Niagen Bioscience, said the partnerships with GNC and Sam’s Club strengthen the company’s retail presence. He emphasized that the expansion reflects credible demand for healthy aging solutions backed by rigorous scientific standards.

The company continues to focus on advancing healthspan through precision science, with its portfolio including consumer supplements and pharmaceutical-grade Niagen products available exclusively at clinics with a prescription.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the distinct product positioning at GNC (beauty-focused) versus Sam’s Club (bulk/value) influence Niagen Bioscience's overall revenue mix and brand perception?

What are the projected incremental sales impacts from these 300 new retail locations compared to the company's existing e-commerce and direct-to-consumer channels?

Could this successful retail expansion accelerate the adoption of pharmaceutical-grade Niagen products, or will consumer supplements remain the primary growth driver?

like15
dislike

More News on Niagen Bioscience